The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Innova Therapeutics receives Rare Pediatric Disease Designation from FDA for IVT-8086 for Osteosarcoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA has granted Rare Pediatric Disease Designation for IVT-8086 for the treatment of Osteosarcoma.

IVT-8086 is a humanized monoclonal antibody with high affinity to a novel anticancer target, secreted frizzled-related protein 2.

The agent is sponsored by Innova Therapeutics Inc.

“IVT-8086 has the potential to become the first FDA-approved therapy for individuals with osteosarcoma in over 30 years,” Robert Ryan, CEO of Innova Therapeutics, said in a statement.

The underlying research was conducted in the laboratory at the Hollings Cancer Center at the Medical University of South Carolina (MUSC) by Nancy Klauber-DeMore, who is a co-founder and professor of surgery and BMW Endowed Chair of Cancer Research.

Table of Contents

YOU MAY BE INTERESTED IN

Health Equity

Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

By Matthew Bin Han Ong
Health Equity

ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.
By Jacquelyn Cobb
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account